Bristol-Myers Squibb Co vs LyondellBasell Industries NV — how do they compare? Bristol-Myers Squibb Co trades at $63.41 (market cap $132.45B), while LyondellBasell Industries NV trades at $63.98 (market cap $20.24B). The key difference: Bristol-Myers Squibb Co is far larger — about 6.5× LyondellBasell Industries NV's market cap, and LyondellBasell Industries NV pays the higher dividend (6.58%). Which is the better fit depends on your goals.
| BMY | LYB | |
|---|---|---|
Market Cap | $132.45B | $20.24B |
Sector | Health | Basic Materials |
52-Week High | $65.89 | $82.38 |
52-Week Low | $42.60 | $42.28 |
Enterprise Value | $166.44B | $31.83B |
Dividend Yield | 3.89% | 6.58% |
Trailing returns across standard periods
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →LyondellBasell Industries NV is a petrochemical producer with operations in the U.S. and Europe. It operates in six segments: Olefins and Polyolefins-Americas (O&P-Americas), Olefins and Polyolefins-Europe, Asia, International (O&P-EAI), Intermediates and Derivatives (I&D), Advanced Polymer Solutions (APS), Refining and Technology. The company is a major producer of polyethylene, the world's largest producer of polypropylene, and the second- largest producer of propylene oxide. Its chemicals are used in various consumer and industrial end products. Substantially, all of the company's revenue is derived from product sales.
Read more on LYB →